Revenue and Profit - Revenue for the third quarter was RMB 80,664,120.99, an increase of 4.74% year-over-year[2] - Net profit attributable to shareholders was RMB 27,675,939.24, a decrease of 12.62% year-over-year[2] - Net profit for the quarter was RMB 71.19 million, a slight decrease from RMB 72.01 million in the same period last year[17] - Sales revenue from goods and services was RMB 243.67 million, a decrease from RMB 285.88 million in the same period last year[19] - Total comprehensive income for the quarter was RMB 71.19 million, compared to RMB 72.01 million in the previous year[18] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 1,850,679,243.44, an increase of 2.24% compared to the end of the previous year[2] - Total assets increased to 1,850,679,243.44 RMB, up from 1,810,100,800.90 RMB in the previous period[15] - Total liabilities rose to 86,011,661.28 RMB, compared to 77,099,673.09 RMB previously[16] - Owner's equity grew to 1,764,667,582.16 RMB, up from 1,733,001,127.81 RMB[16] - The monetary funds at the end of the period amounted to 130,122,749.32 yuan, a decrease from 191,596,438.14 yuan at the beginning of the period[14] - The trading financial assets at the end of the period amounted to 268,204,519.48 yuan, an increase from 152,262,249.57 yuan at the beginning of the period[14] - The accounts receivable at the end of the period amounted to 68,372,501.01 yuan, an increase from 65,395,480.10 yuan at the beginning of the period[14] - Inventory decreased to 33,866,230.33 RMB, down from 39,222,641.95 RMB[15] - Prepayments rose to 13,039,320.38 RMB, compared to 5,716,142.79 RMB previously[15] - Fixed assets increased to 344,316,124.53 RMB, up from 207,054,970.58 RMB[15] - Construction in progress decreased to 131,754,289.00 RMB, down from 156,652,040.89 RMB[15] - Accounts receivable increased to 1,124,389.79 RMB, up from 887,673.85 RMB[15] Cash Flow - Cash flow from operating activities was RMB 107,656,794.88, an increase of 32.44% year-over-year[2] - Cash received from other operating activities increased by 263.24% to RMB 52,258,423.24, mainly due to increased VAT refunds and government subsidies[8] - Cash received from investment recoveries increased by 32.92% to RMB 1,688,246,546.63 due to rolling cash management activities[8] - Total operating cash inflow was RMB 295.93 million, down from RMB 300.26 million in the same period last year[19] - Other income related to operating activities was RMB 52.26 million, a significant increase from RMB 14.39 million in the previous year[19] - Cash outflow from operating activities decreased to 188.27 million yuan from 218.98 million yuan, a reduction of 14.02%[20] - Net cash flow from operating activities increased to 107.66 million yuan from 81.28 million yuan, a growth of 32.45%[20] - Cash inflow from investing activities rose to 1.69 billion yuan from 1.27 billion yuan, an increase of 32.91%[20] - Net cash flow from investing activities improved to -125.53 million yuan from -553.78 million yuan, a significant reduction in outflow[20] - Cash outflow from financing activities decreased to 43.59 million yuan from 56.70 million yuan, a reduction of 23.12%[20] - Net cash flow from financing activities improved to -43.59 million yuan from -56.70 million yuan, a reduction in outflow[20] - Net increase in cash and cash equivalents improved to -61.46 million yuan from -529.20 million yuan, a significant reduction in outflow[20] - Ending cash and cash equivalents balance decreased to 127.07 million yuan from 346.10 million yuan, a reduction of 63.28%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 9,379[9] - Sun Tiansong holds 19.94% of the shares, totaling 52,538,822 shares[9] - Ningbo Kerongda Venture Capital Partnership holds 10.23% of the shares, totaling 26,960,866 shares[9] - Zhang Liebing holds 6.39% of the shares, totaling 16,844,490 shares[9] - Qiao Xiangqian holds 4.51% of the shares, totaling 11,888,100 shares[9] - Ningbo Kehuida Venture Capital Partnership holds 4.42% of the shares, totaling 11,655,768 shares[9] - Liu Xiaojun holds 4.37% of the shares, totaling 11,510,495 shares[9] Expenses and Income - R&D expenses for the quarter were RMB 24.05 million, slightly down from RMB 24.69 million in the previous year[17] - Interest income increased to RMB 20.06 million from RMB 17.10 million in the previous year[17] - Financial expenses showed a negative value of RMB -19.80 million, compared to RMB -16.70 million in the previous year[17] - Income tax expense increased to RMB 8.49 million from RMB 6.77 million in the same period last year[17] - Government subsidies received during the reporting period amounted to RMB 4,136,358.05[3] - Investment income decreased by 64.29% to RMB 1,854,709.79 due to reduced returns from matured financial products[7] Operating Performance - Operating income reached 218,714,979.06 RMB, slightly higher than the previous 216,946,877.08 RMB[16] - Operating costs increased to 152,721,092.56 RMB, up from 148,503,966.53 RMB[16] - Prepaid expenses increased by 128.11% to RMB 13,039,320.38 due to increased prepayments for procurement and services[5] - Fixed assets increased by 66.29% to RMB 344,316,124.53 due to the transfer of some construction-in-progress to fixed assets[5] - Basic and diluted earnings per share remained stable at RMB 0.27[18]

证券代码：300858 证券简称：科拓生物 公告编号：2024-051 北京科拓恒通生物技术股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 5、会议主持人：公司董事长孙天松女士。 6、本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》等规定。 一、会议召开及出席的情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2024年9月11日（星期三）14:30 （2）网络投票时间：2024年9月11日。其中，通过深圳证券交易所交易系统 进行网络投票的具体时间为：2024年9月11日，9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2024年9月11日， 9:15-15:00。 2、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 3、会议召开地点：北京市怀柔区雁栖经济开发区牤牛河路31号院1号-2 公 司会议室。 4、会议召集人：公司董事会。 1、本次股东大会未出现否决议 ...

北 京 市东城区 北三环东路 36 号 环 球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 关 于 北 京 科拓 恒 通生 物 技术 股 份有 限公 司 2024 年 第二 次 临时 股 东大 会 的 法律意见书 北 京 市 君 致律 师 事务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 君致（ ）字[2022] 【文件编号】 号 关于北京科拓恒通生物技术股份有限公司 2024 年第二次临时股东大会的 法律意见书 致：北京科拓恒通生物技术股份有限公司 北京市君致律师事务所（以下简称"本所"）接受北京科拓恒通生物技术股份有限 公司（以下简称"公司"）的委托，指派邓鸿成律师、黄辽希律师见证了公司于 202 ...

| 项目 | | 工作内容 | | --- | --- | --- | | 1、公司信息披露审阅情况 | | | | （1）是否及时审阅公司信息披露文件 | | 是 | | （2）未及时审阅公司信息披露文件的次数 | | 次 0 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | | （1）是否督导公司建立健全规章制度（包括但不限于防 | | | | 止关联方占用公司资源的制度、募集资金管理制度、内控 | | 是 | | 制度、内部审计制度、关联交易制度） | | | | （2）公司是否有效执行相关规章制度 | | 是 | | 3、募集资金监督情况 | | | | （1）查询公司募集资金专户次数 | | 6 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | | 是 | | 4、公司治理督导情况 | | | | （1）列席公司股东大会次数 | 0 | 次，均事前或事后审阅相关文 | | | | 件 | | （2）列席公司董事会次数 | 0 | 次，均事前或事后审阅相关文 | | | | 件 | | （3）列席公司监事会次数 | 0 | 次，均事前或事后审阅相关文 | | | | 件 ...

证券研究报告·公司点评报告·化学制品 科拓生物（300858） 2024H1 业绩点评：加速战略转型，益生菌业 务稳健增长 2024 年 08 月 21 日 买入（维持） | --- | --- | --- | --- | --- | --- | |------------------------------|--------|---------|--------|--------|--------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 369.17 | 299.24 | 346.76 | 442.90 | 557.40 | | 同比（ % ） | 1.25 | (18.94) | 15.88 | 27.72 | 25.85 | | 归母净利润（百万元） | 109.89 | 93.48 | 110.58 | 133.48 | 165.87 | | 同比（ % ） | 0.32 | (14.93) | 18.30 | 20.70 | 24.27 | | EPS- 最新摊薄（元 / 股） | ...

证券研究报告|公司点评报告 [Table_Date] 2024 年 08 月 21 日 [Table_Title] 战略转型效果显现，扣非利润高增 | --- | --- | --- | --- | |-------------------------|----------------------|-----------------------|-------------| | [Table_DataInfo] 评级： | 买入 | 股票代码： | 300858 | | 上次评级： | 买入 | 52 周最高价/最低价： | 21.41/13.37 | | | 目标价格： 总市值(亿 | ) | 37.21 | | 最新收盘价： | 14.12 | 自由流通市值(亿 ) | 27.36 | | | | 自由流通股数(百万 ) | 193.76 | [Table_Summary] 事件概述 公司 24H1 实现营收 1.38 亿元，同比-1.34%，实现归母净利润 4351 万元，同比+7.89%，实现扣非归母净 利润3764万元，同比+17.30%。据此推算，公司24Q2实现营收7903万元，同比+16.58 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period last year[2]. - The company has provided a revenue guidance of RMB 1.1 billion for the full year 2024, which reflects an expected growth of 10% year-over-year[2]. - The company's operating revenue for the first half of 2024 was ¥138,050,858.07, a decrease of 1.34% compared to ¥139,931,675.55 in the same period last year[12]. - Net profit attributable to shareholders increased by 7.89% to ¥43,514,985.46 from ¥40,332,596.67 year-on-year[12]. - The net profit after deducting non-recurring gains and losses rose by 17.30% to ¥37,636,699.24 compared to ¥32,086,539.53 in the previous year[12]. - The gross margin for the first half of 2024 was reported at 45%, a slight increase from 43% in the previous year[2]. - Basic and diluted earnings per share increased by 13.33% to ¥0.17 from ¥0.15 year-on-year[12]. - The company reported a total investment of RMB 1,360.89 million during the reporting period, a decrease of 19.27% compared to the same period last year[64]. - The company reported a total of 60 million RMB in related party transactions with its chief scientist, which is 3.25% of the approved transaction amount of 150 million RMB for the year 2024[108]. Market Expansion and Strategy - User data indicates a growth in active users by 20%, reaching 1.2 million users by the end of June 2024[2]. - Market expansion efforts include entering two new provinces, aiming for a 25% increase in market share by the end of 2024[2]. - The company is actively expanding into the pet food sector, leveraging its expertise in probiotics and micro-ecological solutions[31]. - The company aims to replace imported probiotic strains with locally sourced strains that are better suited to the Chinese gut microbiome[23]. - The company is focusing on enhancing brand recognition and market presence through increased marketing efforts and sales channel expansion[84]. Research and Development - The company is focusing on the development of new probiotic products, with an investment of RMB 50 million allocated for R&D in 2024[2]. - R&D investment accounted for 11.63% of revenue, totaling CNY 16.06 million, with a year-on-year increase of 6.18%[32]. - The company obtained 9 new domestic patents related to probiotics, including 4 invention patents and 5 utility model patents[32]. - The company has established Asia's largest commercial lactic acid bacteria strain resource library, preserving over 40,000 strains as of June 30, 2024[99]. - The company is recognized as a high-tech enterprise and a pilot unit for intellectual property in Beijing, indicating its commitment to innovation and technology[18]. Financial Health and Investments - The net cash flow from operating activities was ¥50,213,593.81, reflecting a 9.95% increase from ¥45,668,510.07 in the same period last year[12]. - Cash and cash equivalents decreased to ¥92,674,705.58, representing 5.10% of total assets, down from 10.58% the previous year[60]. - The company’s trading financial assets increased significantly to ¥310,147,671.23, accounting for 17.05% of total assets, up from 8.41%[60]. - The company’s long-term equity investments stood at ¥2,130,437.52, a slight increase from the previous year[60]. - The company’s total investment in the ecological agent production base project is RMB 11.90 million, with a cumulative actual investment of RMB 150.34 million[67]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[2]. - The company faces competition from multinational corporations like DuPont and Chr. Hansen in the probiotic raw material market, which increases market promotion challenges due to brand recognition gaps[84]. - The company is addressing market volatility risks by strengthening insights into macro environments and customer needs to develop new products[85]. Corporate Governance and Compliance - The company has not declared any cash dividends for the year, focusing instead on reinvestment into growth initiatives[2]. - The company has not reported any significant changes in its main business during the reporting period[18]. - The company adheres to environmental protection laws and has not faced any administrative penalties for environmental issues during the reporting period[98]. - The company emphasizes the protection of employee rights, ensuring compliance with labor laws and providing social insurance benefits[101]. Production and Operations - The company has established a complete R&D, procurement, production, quality inspection, and sales system, with revenue from customized probiotic strain development and transfer becoming a significant income source[41]. - The production of probiotic consumer products follows a monthly sales plan based on market development and expected distribution volume, while raw material production is aligned with customer orders[43]. - The company has implemented a "sales-driven production" model for its products, ensuring that production plans are closely aligned with market demand and customer orders[44]. - The company’s production base in Jinhua utilizes over 5,000 fully automated control points, ensuring product quality and capacity[56]. Shareholder Information - The total number of shares before the recent changes was 263,495,118, with 84,509,971 shares subject to restrictions, accounting for 32.07% of the total[130]. - The largest shareholder, Sun Tiansong, holds 19.94% of the shares, totaling 52,538,822 shares[132]. - The company reported a total of 9,162 shareholders holding more than 5% of the shares at the end of the reporting period[132]. Future Outlook - The company plans to continue expanding its product offerings and market presence through new product development and strategic initiatives[48]. - The report does not provide any future performance guidance or outlook for the upcoming periods[132].

证券代码：300858 证券简称：科拓生物 公告编号：2024-046 北京科拓恒通生物技术股份有限公司 关于使用募集资金相关债权对全资子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2024 年 8 月 19 日召开第三届董事会第九次会议、第三届监事会第九次会议，审议通过《关 于使用募集资金相关债权对全资子公司增资的议案》，同意公司对全资子公司内 蒙古科拓微生态科技发展有限公司（以下简称"科拓微生态"）使用募集资金形 成的部分债权 8,000.00 万元，以债转股的方式对其进行增资，本次增资全部计入 资本公积，不增加科拓微生态的注册资本。本次增资完成后，科拓微生态仍为公 司的全资子公司，公司持股比例为 100%。现将具体情况公告如下： 一、募集资金基本情况 （一）首次公开发行股票 经中国证券监督管理委员会《关于核准北京科拓恒通生物技术股份有限公司 首次公开发行股票的批复》（证监许可[2020]1337 号）核准，公司首次公开发行 人民币普通股（A 股）2,063.00 万股，每股面值为 ...

证券代码：300858 证券简称：科拓生物 公告编号：2024-045 北京科拓恒通生物技术股份有限公司 关于部分募投项目调整内部投资结构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2024 年 8 月 19 日召开第三届董事会第九次会议、第三届监事会第九次会议，审议通过了《关 于部分募投项目调整内部投资结构的议案》，根据《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求（2022 年修订）》《深圳证券交易 所创业板上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规 定，上述事项不涉及募集资金用途变更，在董事会审批范围内，无需提交公司股 东大会审议批准。现将具体情况公告如下： 一、募集资金基本情况 （一）首次公开发行股票 经中国证券监督管理委员会《关于核准北京科拓恒通生物技术股份有限公司 首次公开发行股票的批复》（证监许可[2020]1337 号）核准，公司首次公开发行 人民币普通股（A 股）2,063.00 万股，每股面值为人民币 1.00 元，每股发行价 ...

证券代码：300858 证券简称：科拓生物 公告编号：2024-048 北京科拓恒通生物技术股份有限公司 关于使用闲置自有资金进行现金管理的公告 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2024 年 8 月 19 日召开第三届董事会第九次会议、第三届监事会第九次会议，审议通过了《关 于使用闲置自有资金进行现金管理的议案》，同意公司在确保不影响公司正常经 营及资金安全的情况下，拟使用总额度不超过人民币 50,000.00 万元（含本数） 的闲置自有资金进行现金管理，上述额度自 2024 年第二次临时股东大会审议通 过之日起 12 个月内有效。在前述额度和期限范围内，资金可以循环滚动使用。 具体情况公告如下： 一、使用闲置自有资金进行现金管理的情况 （一）现金管理目的 为提高闲置自有资金使用效率，在确保不影响公司正常经营和资金安全，并 有效控制风险的前提下，公司拟使用暂时闲置的自有资金进行现金管理，以更好 地实现现金的保值增值，保障公司股东的利益。 （二）投资品种 公司拟购买投资由商业银行等金融机构发行的安全性高、流动性好、低风险 且期限最长不超过 36 个月的投资理财产品，包括但不限于商业银行、 ...